The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx

Michał Jarząb; Maria Litwiniuk; Paige Innis; Aleksandra Łacko; Gesine Enderle; Bogumiła Czartoryska-Arłukowicz; Małgorzata Talerczyk; Joanna Streb; Piotr Wysocki; Grażyna Suchodolska; Bartosz Szymanowski; Renata Duchnowska

doi:10.5114/wo.2024.144222

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2024
vol. 28

Send email

Copy url:

abstract:

Original paper

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx

Michał Jarząb

¹

,

Maria Litwiniuk

^{2, 3}

,

Paige Innis

⁴

,

Aleksandra Łacko

⁵

,

Gesine Enderle

⁶

,

Bogumiła Czartoryska-Arłukowicz

⁷

,

Małgorzata Talerczyk

⁸

,

Joanna Streb

^{9, 10}

,

Piotr Wysocki

^{9, 10}

,

Grażyna Suchodolska

¹¹

,

Bartosz Szymanowski

¹²

,

Renata Duchnowska

¹²

Breast Cancer Centre, Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
Department of Clinical Oncology and Immuno-oncology, Greater Poland Cancer Centre, Poznań, Poland
Department of Cancer Pathology and Prevention, Poznań University of Medical Sciences, Poznań, Poland
Exact Sciences Corporation, Redwood City, CA, USA
Lower Silesian Oncology Centre, Medical University of Wrocław, Wrocław, Poland
Exact Sciences International GmbH, Baar, Switzerland
M. Skłodowska-Curie Bialystok Oncology Centre, Białystok, Poland
West Pomeranian Oncology Centre in Szczecin, Szczecin, Poland
Department of Oncology, Jagiellonian University Medical College, Kraków, Poland
Department of Oncology, Krakow University Hospital, Kraków, Poland
Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
Department of Oncology, Military Institute of Medicine – National Research Institute, Warsaw, Poland

Contemp Oncol (Pozn) 2024; 28 (3): 245–252

DOI: https://doi.org/10.5114/wo.2024.144222

Online publish date: 2024/10/15

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Jarząb M, Litwiniuk M, Innis P, et al. The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx. Contemporary Oncology/Współczesna Onkologia. 2024;28(3):245-252. doi:10.5114/wo.2024.144222.

APA

Jarząb, M., Litwiniuk, M., Innis, P., Łacko, A., Enderle, G.,  & Czartoryska-Arłukowicz, B. et al. (2024). The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx. Contemporary Oncology/Współczesna Onkologia, 28(3), 245-252. https://doi.org/10.5114/wo.2024.144222

Chicago

Jarząb, Michał, Maria Litwiniuk, Paige Innis, Aleksandra Łacko, Gesine Enderle, Bogumiła Czartoryska-Arłukowicz,  and Małgorzata Talerczyk et al. 2024. "The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx". Contemporary Oncology/Współczesna Onkologia 28 (3): 245-252. doi:10.5114/wo.2024.144222.

Harvard

Jarząb, M., Litwiniuk, M., Innis, P., Łacko, A., Enderle, G., Czartoryska-Arłukowicz, B., Talerczyk, M., Streb, J., Wysocki, P., Suchodolska, G., Szymanowski, B.,  and Duchnowska, R. (2024). The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx. Contemporary Oncology/Współczesna Onkologia, 28(3), pp.245-252. https://doi.org/10.5114/wo.2024.144222

MLA

Jarząb, Michał et al. "The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx." Contemporary Oncology/Współczesna Onkologia, vol. 28, no. 3, 2024, pp. 245-252. doi:10.5114/wo.2024.144222.

Vancouver

Jarząb M, Litwiniuk M, Innis P, Łacko A, Enderle G, Czartoryska-Arłukowicz B et al. The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx. Contemporary Oncology/Współczesna Onkologia. 2024;28(3):245-252. doi:10.5114/wo.2024.144222.

PlumX metrics:

Introduction:
Breast cancer (BC) is among the most frequently diagnosed malignant tumours in females. The optimal treatment of early HR+, HER2–, and lymph node-negative (N0) BC remains challenging. Since individual assessment of recurrence risk and expected benefits from adjuvant chemotherapy (CT) based on clinicopathological features alone appear inadequate, gene expression profiling tests have been developed. This study aimed to evaluate the impact of Oncotype DX Breast Recurrence Score^® (Oncotype DX Breast RS) test results on physicians’ decisions concerning adjuvant CT in the Polish population.

Material and methods:
The PONDx survey investigated the real-life use of Oncotype DX Breast RS in 204 patients with HR+, HER2–, N0 BC in 8 clinical reference centres in Poland. Data on clinicopathological features and changes in treatment based on the Oncotype DX Breast RS test were collected.

Results:
Chemotherapy plus endocrine therapy (ET) was initially recommended in 44.8% and ET alone in 55.2% of patients. After the introduction of recurrence score results, the recommendation for CT decreased significantly: relative reduction of 25.5% (95% CI: 11.7–52.3) and absolute reduction of 11.4% (95% CI: 1.9–21.0). Among patients initially recommended for CT, treatment was de-escalated in 62.2%; conversely, among patients initially recommended for ET alone, 29.7% were escalated to CT after testing. The relative reduction was especially pronounced in post-menopausal patients (29.6%) and in those with lobular BC (42.9%).

Conclusions:
The Oncotype DX Breast RS result significantly influenced treatment decisions, with 44.3% of patients changing treatment, thus avoiding overtreatment or undertreatment. The Oncotype DX Breast RS test improves patient management and increases physician confidence in treatment recommendations.

keywords:

The utility of the 21-gene Oncotype DX Breast Recurrence Score® assay in node-negative breast cancer patients – the final analysis of the Polish real life survey PONDx

Michał Jarząb 1 , Maria Litwiniuk 2, 3 , Paige Innis 4 , Aleksandra Łacko 5 , Gesine Enderle 6 , Bogumiła Czartoryska-Arłukowicz 7 , Małgorzata Talerczyk 8 , Joanna Streb 9, 10 , Piotr Wysocki 9, 10 , Grażyna Suchodolska 11 , Bartosz Szymanowski 12 , Renata Duchnowska 12

breast cancer, Oncotype DX Breast Recurrence Score®, adjuvant chemotherapy, real life study